Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Synbiotics Corp. -- Ignore unavailable to you. Want to Upgrade?

To: E.J. Neitz Jr who wrote (19)	1/9/1998 7:58:00 PM
From: E.J. Neitz Jr	Respond to of 37

ALERT-- New Product Approval-Feline Heartworm-Only kit on the Market!! Synbiotics Corp. Gains Approval For New Product SAN DIEGO--(BUSINESS WIRE)--Jan. 6, 1998--Synbiotics Corp. (NASDAQ:SBIO) Tuesday announced that it has received regulatory approval to market ASSURE/FH, a proprietary diagnostic test to detect antibody against heartworm infection in cats. Synbiotics' customers will begin receiving shipments in a few days. Synbiotics' ASSURE/FH is the first product in the United States to offer veterinarians a simple and accurate way to test cats in the vet's office for exposure to the heartworm parasite. Previously, this infection could only be reliably detected by sending blood samples to a laboratory. Heartworm, a parasite carried by mosquitos, is widely known as an infection in dogs; its diagnosis, prevention and treatment represent an important aspect of veterinary practice and a major market in animal health. While cats are infected less often than dogs, the effects of feline heartworm can be severe, even fatal, and can occur without warning. It's for this reason that feline heartworm infection is of rising concern to veterinarians and owners of the more than 60 million cats in the United States. According to Dr. Mike Harrod, Synbiotics' director of veterinary services: "Heartworm can be dangerous, even fatal, to cats who may exhibit no apparent signs of illness. With simple, rapid testing now available in the vet's office, cat owners should consult with their veterinarians about regular testing and preventive medication." Ken Cohen, Synbiotics' president and chief executive officer, added: "Canine heartworm testing provides a great benefit to dogs and their owners, and a strong contribution to Synbiotics' business. With the cat population outnumbering that of dogs and the growing awareness of feline heartworm, our innovative development and launch of ASSURE/FH offers the potential for substantial value to our customers and to our company." Synbiotics develops, manufactures and markets animal health products under its own name in the United States and internationally through licensees. With the exception of historical matters, the issues discussed in this press release are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including competition from larger companies, reliance on third-party manufacturers and distributors, possible technology improvements by others, intellectual property rights issues, the ability to assimilate acquired businesses, the seasonality of major portions of the company's business and other risks set forth in the company's filings with the Securities and Exchange Commission, particularly Form 10-KSB filed for the year ended Dec. 31, 1996 and Form 10 QSB filed for the quarter ended Sept. 30, 1997. Actual results may differ materially from those projected. These forward-looking statements represent the company's judgment as of the date of the release. The company disclaims, however, any intent or obligation to update these forward-looking statements. CONTACT: Synbiotics Corp. Michael K. Green, 619/451-3771 mikeg@synbiotics.com or Kenneth M. Cohen, 619/451-3771 kenc@synbiotics.com or Financial Relations Board Fiona Ross, 310/442-0599 or Kathy Brunson, 312/266-7800

To: E.J. Neitz Jr who wrote (19)	1/9/1998 8:02:00 PM
From: E.J. Neitz Jr	Read Replies (1) \| Respond to of 37

ALERT- NEWS---SBIO Launches New Product Synbiotics Corp. Launches Product SAN DIEGO--(BW HealthWire)--Dec. 1, 1997--Synbiotics Corp. (NASDAQ:SBIO) Monday announced that it has received regulatory approval to market D-TEC CB, a proprietary diagnostic test for canine brucellosis. Synbiotics' customers will begin receiving shipments this week. Brucellosis is an infection in dogs caused by the bacterial organism "Brucella canis." It is of special concern to veterinarians and dog breeders because of its impact on canine reproduction. Symptoms of the disease can include impotence and sterility in the male, infertility in females and loss of unborn puppies. The American Kennel Club (AKC) recommends that all dogs used for breeding have two negative tests, 30 days apart. While the total number of dog breedings is not known, each year there are approximately 750,000 purebred dog litters born to the approximately 22 million purebred dogs in the United States. According to Ken Cohen, Synbiotics president and chief executive officer, "D-TEC CB represents a substantial opportunity for Synbiotics. It complements our market-leading position in products and services for canine reproduction. It's something our customers have been asking for, and we are manufacturing with existing resources in San Diego." Synbiotics previously marketed another product also known as D-TEC CB which was manufactured by a third party. The new product, however, was developed and will be manufactured by Synbiotics. Synbiotics develops, manufactures and markets veterinary diagnostics, vaccines and related animal-health products. For more information, please visit Synbiotics' Web site at stockprofiles.com . With the exception of historical matters, the issues discussed in this press release are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including patent litigation relating to heartworm diagnotics, competition from larger companies, reliance on third-party manufacturers and distributors, possible technology improvements by others, the ability to assimilate acquired businesses, the seasonality of major portions of the company's business and other risks set forth in the company's filings with the Securities and Exchange Commission, particularly Form 10-KSB filed for the year ended Dec. 31, 1996. Actual results may differ materially from those projected. These forward-looking statements represent the company's judgment as of the date of the release. The company disclaims, however, any intent or obligation to update these forward-looking statements. CONTACT: Synbiotics Corp., San Diego Michael K. Green, 619/451-3771 mikeg@synbiotics.com Kenneth M. Cohen, 619/451-3771 kenc@synbiotics.com or Financial Relations Board Fiona Ross, 310/442-0599 Kathy Brunson, 312/266-7800